OOIR: Observatory of International Research

Papers

(The H4-Index of Nature Reviews Drug Discovery is 81. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
The importance of persistence in cancer drug development	1888
A new path to targeted protein degradation?	1791
A specific biomarker for insoluble tau	1139
Targeting tumour-associated bacteria	1093
The improving benefit–risk balance of phase I cancer trials	969
Neutralizing Zika virus	743
Upcoming market catalysts in Q3 2021	651
Vaccine exposes tumours to immune cell attack	556
Pfizer buys Biohaven’s migraine drugs for $11.6 billion	549
Promoting tissue repair after heart attack	490
mRNA-encoded monoclonal antibody fights CHIKV	488
AI serves up target and inhibitor for lung fibrosis	484
FDA approves first all-oral sleeping sickness drug	408
Hypoimmune iPSCs escape immune detection	404
Glucose-sensitive insulin protects against hypoglycaemia	402
Tumour cells get a dendritic cell makeover	402
Degrading cell-free DNA to prevent recurrent stroke	372
Apolipoprotein L2 inhibitor mitigates fibrosis	368
FDA new drug approvals in Q1 2023	368
Lipid nanoparticle ferries therapeutic mRNA to the placenta	365
FDA approves second TTR stabilizer for cardiac amyloidosis	362
BRAF plus MEK inhibitor combo secures tumour-agnostic FDA approval	356
Targeting drug-resistant glioblastoma	345
First-in-class IL-15 receptor agonist nabs FDA approval for bladder cancer	337
New antibiotic for urinary tract infections nabs FDA approval	317

Chemical engineering of CRISPR–Cas systems for therapeutic application	279
2022 FDA approvals	273
Anti-tau antibody stumbles in phase II Alzheimer trial	254
Evolution of innovative drug R&D in China	252
Top companies and drugs by sales in 2021	249
Small-molecule discovery through DNA-encoded libraries	245
mRNA vaccines for infectious diseases — advances, challenges and opportunities	242
Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets	238
Increasing the potency of T cell therapies	222
Pushing both sides of the drug pricing aisle	218
Predicting Alzheimer disease dementia	207
Reflections on 10 years of the FDA’s breakthrough therapy designation	204
Blocking breast cancer metastasis	194
Rewired proteostasis in KRAS inhibitor resistance	192
Small molecule improves muscle function in myasthenia gravis	189
FDA approves anti-CD3 antibody to delay type 1 diabetes onset	182
R&D re-balancing act	181
Host-directed antiviral blocks SARS-CoV-2 entry	177
Author Correction: mRNA vaccines for infectious diseases: principles, delivery and clinical translation	159
The significance of blockbusters in the pharmaceutical industry	157
Screening ultra-large virtual libraries	156
TCR-engineered T cells get personal	156
A call to action for translational sciences in COVID-19 and future pandemics	155
FDA new drug approvals in Q2 2023	153
‘Bespoke Gene Therapy Consortium’ sets out to enable gene therapies for ultra-rare diseases	151
A call to adapt the regulation of HLA testing for T cell receptor-based therapeutics	146
Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape	145
Biomarker-guided decision making in clinical drug development for neurodegenerative disorders	143
Base editors hit the clinic	143
The antibody–drug conjugate landscape	142
The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap	138
FDA approves second BCMA-targeted CAR-T cell therapy	136
FDA approves first DLL3 × CD3 bispecific T-cell engager for lung cancer	131
Author Correction: Identification of neoantigens for individualized therapeutic cancer vaccines	130
Amylin takes another shot at the obesity prize	117
Pan-coronavirus vaccine pipeline takes form	113
Combating antimicrobial resistance in malaria, HIV and tuberculosis	112
Inhibiting ASGR1 boosts cholesterol removal	111
Phenotypic drug discovery: recent successes, lessons learned and new directions	108
The emerging role of mass spectrometry-based proteomics in drug discovery	107
Antibody–drug conjugates come of age in oncology	107
Zebrafish disease models in drug discovery: from preclinical modelling to clinical trials	105
Gut metabolite mediates nerve repair	101
Reducing IL-2 toxicity	100
Agonist antibody lowers blood pressure	100
Immunology on the brain	99
A novel single-agent antibiotic	99
Multi-TACs target solid tumours	94
The malignant melanoma market	92
What does AlphaFold mean for drug discovery?	90

FDA approves J&J’s FcRn blocker for generalized myasthenia gravis	85
Neglected tropical diseases go global	85
Monkeypox mRNA vaccine protects mice and macaques	85
Anti-IL-11 antibody shows anti-ageing properties	84
The European Innovation Network as a hub for medicines innovation in Europe	84
GSK buys Affinivax for up to $3.3 billion, bolstering its vaccine pipeline	81